Full Text View
Tabular View
No Study Results Posted
Related Studies
6-Methyl-Prednisolone for Multiple Organ Dysfunction Syndrome (NAIF)
This study is currently recruiting participants.
Verified by Hospital Principe de Asturias, May 2008
First Received: August 8, 2005   Last Updated: May 12, 2008   History of Changes
Sponsor: Hospital Principe de Asturias
Collaborator: Pfizer
Information provided by: Hospital Principe de Asturias
ClinicalTrials.gov Identifier: NCT00127985
  Purpose

Background: Systemic corticosteroids are considered in patients with an adverse clinical course suffering from conditions like the acute respiratory distress syndrome (ARDS) and septic shock. Treated patients not only show improved respiratory function, but also hemodynamic status and overall multiple organ dysfunction score.

Objective: To evaluate the safety and effectiveness of 6-methyl-prednisolone on the clinical course of multiple organ dysfunction syndrome (MODS).

Design: Multi-center, double-blind, randomized, placebo-controlled.

Intervention: Intravenous administration of 6-methyl-prednisolone or placebo (aqueous solution). The duration of the study medication administration protocol is 32 days (1).

Primary Endpoints:

  1. All cause Intensive Care Unit (ICU) and 28-day mortality
  2. Organ dysfunction score on days 4, 7, 14, and 28 of the protocol.

Condition Intervention Phase
Multiple Organ Dysfunction Syndrome
Drug: 6-methyl-prednisolone
Phase IV

Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title: The Effect of 6-Methyl-Prednisolone on Organ Dysfunction and Mortality of Patients With Unresolving Multiple Organ Dysfunction Syndrome

Resource links provided by NLM:


Further study details as provided by Hospital Principe de Asturias:

Primary Outcome Measures:
  • All cause ICU and 28-day mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Organ dysfunction score on days 4, 7, 14, and 28 of the protocol [ Time Frame: Days 4, 7, 14, and 28. ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Mortality [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Morbidity: Duration of mechanical ventilation and endotracheal intubation (also a surrogate for acute steroid myopathy) [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • Length of ICU-stay [ Time Frame: 28 days ] [ Designated as safety issue: No ]
  • Complications of steroid therapy [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • Infections acquired during the protocol [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • Other complications (hyperglycemia, GI bleeding, acute myopathy, pneumothorax) [ Time Frame: 28 days ] [ Designated as safety issue: Yes ]
  • Adrenal reserve as evaluated by adrenocorticotropic hormone (ACTH) test. [ Time Frame: Baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 240
Study Start Date: August 2005
Estimated Study Completion Date: July 2008
Estimated Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active: Experimental
IV 6-methyl-prednisolone
Drug: 6-methyl-prednisolone
iv, 2 mg/kg/day, qid
Comparator: Placebo Comparator
IV Placebo
Drug: 6-methyl-prednisolone
iv, 2 mg/kg/day, qid

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Main Inclusion Criteria:

Patients with established, unresolving, refractory MODS, in whom all reversible and treatable causes of persistent MODS have been treated or ruled out:

  • Patients under endotracheal intubation and mechanical ventilation for at least 7 days.
  • Aggregate Multiple Organ Dysfunction Score (5) of greater than 8 over the first seven days of mechanical ventilation and greater than 5 on the day of inclusion.
  • Written informed consent to participate in the trial signed by next of kin or other authorized person.

Additional Inclusion Criteria:

  • Main cause or disease at admission: Adequate "source control" is required and refers to optimal, complete, and definitive surgical and/or medical therapy.
  • Infections:

    1. Infectious causes of persistence of MODS have reasonably been ruled out on clinical or other grounds (infectious endocarditis, undrained abscesses like sinusitis, empyema or abdominal pus). Consider sampling for culture of broncho-alveolar lavage fluid, protected specimen brush or other (empyema fluid, lung tissue) in order to rule out respiratory infection, as well as intra-vascular catheter change and culture.
    2. Present or previous infections, either documented or strongly suspected, have been treated for at least 3 days before inclusion.
  • Supportive Care: Optimal hemodynamic, renal, hematologic, nutritional "supportive care" is provided.

Exclusion Criteria:

  • Decision not to provide full support.
  • Immune status and steroid therapy.

    1. Steroid therapy

      • Currently indicated for chronic or concurrent disease (meningitis, auto-immune disease, asthma, acute exacerbation of chronic obstructive pulmonary disease [COPD], or other). Inhaled steroids are allowed.
      • Administered during current admission (> 20 mg/day of 6-methyl-prednisolone or equivalent for >48 hours).
      • Chronic steroid therapy prior to current admission (> 20 mg of 6-methyl-prednisolone or equivalent/day for > 1 month during previous 3 months).
    2. Other immune-suppressive therapy within the previous 6 months.
    3. Known AIDS.
    4. Neutropenia < 500/mcl.
    5. Preceding organ transplantation.
  • Irreversible and or ultimately fatal clinical conditions like metastatic malignant disease or cardiogenic shock caused by coronary artery disease.
  • Presence of invasive fungal infection
  • Other significant pre-existing underlying chronic diseases:

    1. Severe parenchymal liver disease (Child-Pugh grade C)
    2. Severe and irreversible acute or chronic central nervous system disease.
    3. Severe end-stage chronic obstructive pulmonary disease (home oxygen or more than 1 exacerbation in previous year)
    4. End-stage renal disease (Chronic dialysis).
  • Age less than 18 years.
  • Pregnancy.
  • Morbid obesity: body mass index above 40.
  • Recent (last 3 months) upper gastrointestinal [GI] hemorrhage.
  • Extensive burns (>30% body surface area [BSA])
  • Known allergy to steroids.
  • Written informed consent not available.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00127985

Contacts
Contact: Miguel Sanchez, MD, PhD 34-91-887-8100 ext 2205 miguelsanchez.areachip@wanadoo.es

Locations
Spain
Hospital Clinic Recruiting
Barcelona, Spain
Contact: Antoni Torres, MD, PhD            
Principal Investigator: Antoni Torres, MD, PhD.            
Sub-Investigator: Juan Ramón Badía, MD, PhD            
Hospital Universitario de la Princesa Recruiting
Madrid, Spain, 28006
Contact: Antonio Reyes, MD., PhD.     34-91-520-2200     Areyes.hlpr@salud.madrid.org    
Contact: Fernando Lopez, MD., PhD.     34-91-520-2200     fld@inicia.es    
Principal Investigator: Antonio Reyes, MD., PhD.            
Sub-Investigator: Fernando - Lopez, MD, PhD            
Francisco Ortuño Anderiz Recruiting
Madrid, Spain, 28040
Contact: Francisco - Ortuño Anderiz, MD     34-91-330-3223     portunoa@yahoo.es    
Sub-Investigator: Fernando - Martinez Sagasti, MD, PhD            
Clinica Moncloa Recruiting
Madrid, Spain
Contact: Manuel Alvarez, MD, PhD.            
Contact: Juan Jose Oñoro, MD            
Principal Investigator: Manuel Alvarez, MD, PhD            
María Mar Cruz Acuaroni Recruiting
Toledo, Spain, 45004
Contact: Maria Mar - Cruz Acuaroni, MD     34-925-26-9237     mdelca@sescam.jccm.es    
Contact: Maria José - Pérez Pedrero, MD     34-925-26-9237        
Principal Investigator: Maria Mar - Cruz Acuaroni, MD            
Sub-Investigator: Maria Jose - Perez Pedrero, MD            
Spain, Madrid
Hospital Principe de Asturias Recruiting
Alcala de Henares, Madrid, Spain, 28805
Contact: Raul De Pablo     34-91-8871-8100 ext 2205     rdepablosanchez@yahoo.es    
Principal Investigator: Raul De Pablo, MD            
Sponsors and Collaborators
Hospital Principe de Asturias
Pfizer
Investigators
Study Chair: Miguel Sanchez, MD, PhD Hosp. Univ. Principe de Asturias
  More Information

Publications:
Responsible Party: Hospital Principe de Asturias ( Miguel Sanchez Garcia, MD, PhD )
Study ID Numbers: NAIF6MPMODS088UNK9071296
Study First Received: August 8, 2005
Last Updated: May 12, 2008
ClinicalTrials.gov Identifier: NCT00127985     History of Changes
Health Authority: Spain: Ministry of Health

Keywords provided by Hospital Principe de Asturias:
multiple organ dysfunction syndrome
corticosteroids
mortality

Additional relevant MeSH terms:
Anti-Inflammatory Agents
Methylprednisolone
Antineoplastic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Antiemetics
Prednisolone acetate
Hormones
Neuroprotective Agents
Pathologic Processes
Therapeutic Uses
Syndrome
Multiple Organ Failure
Methylprednisolone Hemisuccinate
Disease
Antineoplastic Agents, Hormonal
Gastrointestinal Agents
Methylprednisolone acetate
Protective Agents
Glucocorticoids
Pharmacologic Actions
Shock
Autonomic Agents
Prednisolone
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on February 08, 2010